Showing 21 - 40 results of 45 for search 'Ding Ning', query time: 0.06s Refine Results
  1. 21
  2. 22
  3. 23
  4. 24
  5. 25
  6. 26
  7. 27
  8. 28
  9. 29
  10. 30
  11. 31
  12. 32
  13. 33
  14. 34
  15. 35
  16. 36
  17. 37
  18. 38
  19. 39
  20. 40

    Clinical Outcomes of Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab for Treating Hepatocellular Carcinoma and Type IV Portal Vein Tumor Thrombus by Li X, Cao K, Fu Z, Chen X, Zhong J, Liu L, Ding N, Zhang X, Qu Z, Zhu L, Zhai J

    Published 2025-01-01
    “…Xiaowei Li,* Kunkun Cao,* Zhigang Fu,* Xiaoxia Chen, Jiaming Zhong, Li Liu, Ning Ding, Xiaoli Zhang, Zengqiang Qu, Lijun Zhu, Jian Zhai Department II of Interventional Radiology, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, 200438, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jian Zhai; Lijun Zhu, Department II of Interventional Radiology, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, 200438, People’s Republic of China, Email jianzhai1979@126.com; lijun_zhush@163.comPurpose: To assess the activity and toxicity of hepatic arterial infusion chemotherapy (HAIC)+tislelizumab+lenvatinib (HAIC+tisle+len) in hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) type IV (Vp4 hCC) in a real-world context.Methods: Fifty-five patients, with Vp4 hCC receiving HAIC+tisle+len therapy from April 2021 to December 2022, were analyzed retrospectively. …”
    Get full text
    Article